|1.||Cha, Bong Soo: 13 articles (01/2013 - 01/2005)|
|2.||Lee, Hyun Chul: 12 articles (01/2013 - 01/2005)|
|3.||Kang, Eun Seok: 11 articles (01/2013 - 08/2005)|
|4.||Jones, Nigel P: 9 articles (06/2015 - 11/2003)|
|5.||Derosa, Giuseppe: 9 articles (12/2011 - 05/2004)|
|6.||Ahn, Chul Woo: 9 articles (07/2008 - 01/2005)|
|7.||Nuutila, Pirjo: 8 articles (02/2014 - 12/2002)|
|8.||Gerstein, Hertzel C: 8 articles (03/2011 - 10/2006)|
|9.||Kravitz, Barbara G: 7 articles (04/2013 - 12/2006)|
|10.||McGuire, Darren K: 7 articles (04/2013 - 06/2007)|
07/01/2005 - "Insulin resistance indices were significantly improved after rosiglitazone treatment (P < 0.05). "
08/01/1997 - "BRL 49653 ameliorates insulin resistance and improves glucoregulation in high-fat-fed (HF) rats. "
01/01/2005 - "Rosiglitazone monotherapy improved insulin resistance but not overall beta-cell secretion. "
09/01/1999 - "Rosiglitazone is effective against insulin resistance]."
12/01/2014 - "Rosiglitazone, a PPARγ agonist, ameliorates palmitate-induced insulin resistance and apoptosis in skeletal muscle cells."
|2.||Type 2 Diabetes Mellitus (MODY)
09/01/2010 - "These data suggest that the PGC-1α Thr394Thr and Gly482Ser polymorphisms are associated with therapeutic efficacy of multiple-dose rosiglitazone in Chinese patients with type 2 diabetes mellitus."
01/01/2005 - "Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus."
04/01/2010 - "Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus."
10/01/2007 - "The objective of this study was to determine if rosiglitazone (RSG) reduced the odds of restenosis and if RSG improved the odds of clinical outcomes after percutaneous coronary intervention (PCI) in type 2 diabetes mellitus (DM) patients. "
09/01/2003 - "To assess the clinical safety and efficacy of rosiglitazone maleate in the treatment of patients with type 2 diabetes mellitus. "
04/01/2008 - "A significant reduction in HOMA-R, markers of inflammation and oxidative stress was only observed with rosiglitazone. "
08/14/2012 - "The protective effects of rosiglitazone against MCT-induced PH are correlated with drug dose and may be due to the inhibition of inflammation."
01/01/2011 - "The peroxisome proliferator-activated receptor-γ (PPARγ) agonist rosiglitazone has been suggested to exert cardiovascular protection through the improvement of lipid metabolism, anti-inflammation, anti-proliferation etc. However, whether renin-angiotensin system (RAS) is involved in the vascular protective effects of PPARγ agonists is not fully understood. "
12/01/2011 - "In addition, adipose mass, adipocyte cross-sectional area and inflammation were improved with rosiglitazone. "
09/01/2011 - "PPARγ agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway."
|4.||Body Weight (Weight, Body)
09/01/2007 - "Rosiglitazone (Rosi), despite marked improvement in glycaemia, hyperinsulinaemia and hyperlipidaemia, failed to affect SREBP-1 expression, and increased body weight and IMTG. "
08/01/2000 - "The two rexinoids also produced a marked decrease in the body weight gain, whereas the growth rate of rats treated with BRL 49653 tended to increase. "
08/01/2010 - "Compared to placebo, rosiglitazone treated patients had a higher (mean + or - SD) body weight (89 + or - 15 kg vs. 84 + or - 15 kg, P=0.02) at the end of the study, mostly related to an increment in subcutaneous adipose tissue. "
10/01/2006 - "The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight. "
02/01/2014 - "Rosiglitazone administered by gavage at 20 mg/kg body weight (BW) daily served as a therapeutic control. "
08/01/2015 - "Herbal formulation, DIA-2 and Rosiglitazone ameliorates hyperglycemia and hepatic steatosis in type 2 diabetic rats."
02/01/2001 - "To determine the efficacy of rosiglitazone compared with placebo in reducing hyperglycemia. "
01/01/2014 - "The present study shows that Apom expression is significantly affected by either rosiglitazone or hyperglycemia alone without cross interaction with each other, which indicates that the pathway of Apom expression regulating by hyperglycemia might be differed from that by rosiglitazone. "
04/01/2009 - "Practice Pearl: This study demonstrates the effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy. "
04/01/2009 - "Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study."
|2.||Transplantation (Transplant Recipients)
|5.||Homologous Transplantation (Allograft)